secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001171843-24-005439
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst begins Phase 1 trial of BCX17725 (KLK5 inhibitor) for Netherton syndrome
--------------------------------------------------------------------------------

- First participant enrolled in Phase 1 trial of BCX17725, a KLK5 inhibitor for Netherton syndrome.
- Trial to evaluate safety, tolerability, PK and immunogenicity in healthy adults and Netherton patients.
- Initial data from the trial expected by end of 2025; no approved treatments currently exist for the disease.
- BCX17725 is BioCryst's first protein therapeutic to advance to the clinic.
- Netherton syndrome is an ultra-rare, life-threatening genetic disorder affecting skin, hair, and immune system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324005439/0001171843-24-005439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324005439/f8k_100224.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-005439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer